A case of denosumab-associated hyperparathyroidism: A differential diagnostic challenge

<p>Denosumab is a relatively new medicine that has become the second option in the treatment of biphosphonate-resistant or intolerant osteoporosis. Subcutaneous injection with 6-month intervals, approval of its usage in stage 3-4 CKD and not having gastrointestinal side effects are advantages...

Full description

Saved in:
Bibliographic Details
Main Authors: Emin Taşkıran (Author), Sevnaz Şahin (Author), Sumru Savaş (Author), Zeliha Fulden Saraç (Author), Selahattin Fehmi Akçiçek (Author)
Format: Book
Published: International Journal of Immunotherapy and Cancer Research - Peertechz Publications, 2021-10-08.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items